An immunoinformatics program focused on PRAME (a cancer-testis antigen expressed in subsets of BC) constructed a multi-epitope vaccine whose predicted properties included non-allergenicity, favorable hydrophilicity, and in-silico engagement of Toll-like receptor 4 (TLR4) and interleukin-1 receptor (IL-1R); codon optimization and cloning were shown computationally. Here, TLR4 is linked to breast cancer.